You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Based on the results of the new studies, the Norwegian company is positioning its calprotectin test as an alternative to conventional ELISAs.
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.
The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The initiative includes academic and private sector partners and aims to train new researchers in the early diagnosis of brain cancer.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.